Skip to content
Clinical ResearchResearch compound

Anavar (Oxandrolone)

Oral anabolic steroid once approved for recovery after burns (US approval withdrawn in 2023), also used by bodybuilders; damages the liver and is banned on the doping list.

Available at

The links above are labelled third-party affiliate links. MolekulaX does not sell and does not verify product quality.

Anavar (Oxandrolone) vial

DETAILED OVERVIEW

What is Anavar (Oxandrolone)?

Anavar (Oxandrolone) is an anabolic-androgenic steroid taken by mouth, which means it imitates the action of testosterone. In the United States it was approved as a prescription medicine for recovery after severe burns and for wasting linked to HIV, but the FDA withdrew the approval in 2023; in Hungary it is strictly prescription-only. Bodybuilders and athletes also use it off-label to build muscle.

It damages the liver: liver enzymes can rise and bile flow can become blocked. It can sharply lower HDL cholesterol, which raises the risk of heart and blood vessel problems; it suppresses the body's own testosterone production and can reduce fertility. In women it can cause a deep voice, hair growth and menstrual problems, which can become irreversible. It must not be used in pregnancy, because it can harm the baby and cause masculinization. It also strengthens the blood thinner warfarin, which carries a risk of bleeding. It is banned on the anti-doping list all year round.

Mechanism

AR agonist, 17α-alkylated, no aromatization

Anabolic:Androgenic

320:24

Half-life

9 hours

Onset

1-2 h (oral)

Legal status

FDA approval withdrawn (2023), WADA banned

Data console

Lab data

Androgenic:Anabolic320:24
AR bindingAR affinity moderate; low androgenic potential…
Active half-life9 h
Detection windowOxandrolone metabolites urinary 3 weeks. Short half-life and fast clearance give shorter window than injected AAS.
AromatizationNo – 17α-alkylated steroid, NOT a CYP19 substrate; minimal estrogen conversion (Schänzer 1996 Clin Chem)
HepatotoxicityHigh – 17α-alkylated structure metabolized via hepatic first-pass; dose-dependent transaminase elevation, cholestasis risk (Hartgens-Kuipers 2004)

Safety

Side effects, stop signs, contraindications

Side effects · 7

  • Severe lipid deterioration: drastic HDL drop (up to 30-50%) and LDL rise; oral 17-alpha-alkylated AAS hit lipids harder than many injectables, raising cardiovascular/atherosclerosis risk.
  • Hepatotoxicity: dose-dependent transaminase (ALT/AST) elevation and cholestasis risk from the 17-alpha-alkylated structure; milder than Dianabol or Superdrol, but liver monitoring is still mandatory.
  • HPTA suppression and reduced fertility: dose-dependent inhibition of natural testosterone production (40-60% after 6 weeks), suppressed spermatogenesis; PCT (Clomid/Nolvadex) may be needed for recovery.
  • Virilization in women: voice deepening, hirsutism, clitoral enlargement, menstrual disturbances; above 10 mg/day and beyond 6 weeks these can become IRREVERSIBLE, stop immediately at any sign.
  • Androgenic effects: acne-prone skin, increased sebum, and accelerated hair loss (androgenetic alopecia) in genetically predisposed users, since oxandrolone is a DHT derivative.
  • Elevated blood pressure and altered glucose handling: AAS can cause hypertension; oxandrolone improves glucose sensitivity, which can cause hypoglycemia alongside insulin/antidiabetics.
  • Increased INR with warfarin: oxandrolone potentiates oral anticoagulants, with significant bleeding risk; dose reduction and close INR monitoring are required.

Contraindications · 7

  • Pregnancy and breastfeeding: virilization and teratogenic risk to the fetus, absolute contraindication.
  • Prostate or breast carcinoma (or breast cancer with hypercalcemia): androgenic stimulation can worsen hormone-sensitive tumors.
  • Pre-existing liver disease or elevated liver enzymes: hepatitis B/C, fatty liver, cholestasis, ALT/AST >2x normal; the 17-alpha-alkylation adds further hepatic injury.
  • Severe cardiovascular disease: uncontrolled hypertension, coronary artery disease, heart failure or pre-existing dyslipidemia, since Anavar further worsens the lipid profile.
  • Concurrent warfarin/oral anticoagulant therapy without close monitoring: unpredictable INR rise and bleeding hazard.
  • Planned fatherhood in the near future: HPTA suppression and reduced spermatogenesis, with recovery that can take months.
  • Severe renal impairment or hypercalcemia: AAS can cause fluid retention and calcium metabolism disturbance.

Related Performance Compounds

Same therapeutic category

Studies

Related research and clinical findings

Telegram

Have a question about Anavar (Oxandrolone)?

Reach out to an advisor on Telegram. Performance compounds are presented with a harm-reduction approach, based on peer-reviewed evidence.

Personalized consultation

Want a detailed conversation tailored to your data?

Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.

Fill out the form

~5–7 min · prep questionnaire · confidential · GDPR-compliant

MolekulaX Editorial Team·Source-verified · PubMed · FDA · EMA
Updated: October 13, 2026

The information here is for educational and scientific purposes only. Performance-enhancing compounds (AAS, prohormones, stimulants, doping agents) are illegal without prescription in Hungary and most of the EU, and carry serious health and legal risks. WADA bans them in competitive sport. This is NOT a usage guide, and we do not encourage any illegal use. If you do use them, medical supervision and regular bloodwork are ESSENTIAL. Severe endocrine, cardiovascular, hepatic and psychiatric side effects are possible.